Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections. - Full Text View

Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

This study has been terminated.

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00463762

Purpose

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Condition	Intervention	Phase
Abscess, Intra-Abdominal Cholecystitis Wound Infections Peritonitis Appendicitis	Drug: CP-75385-02 Cefoperazone/sulbactam	Phase IV

MedlinePlus related topics:

Appendicitis

ChemIDplus related topics:

Sulbactam Sulbactam sodium Cefoperazone sodium Cefoperazone

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Cross-Sectional, Defined Population, Prospective Study

Official Title:	Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.

Further study details as provided by Pfizer:

Estimated Enrollment:	200
Study Start Date:	May 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female patient of age 18 years or older.
Patient with intraabdominal/hepatobiliary infection.?

Exclusion Criteria:

Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00463762

Sponsors and Collaborators

Pfizer

Investigators


Study Director:	Pfizer CT.gov Call Center	Pfizer

More Information

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

Study ID Numbers:	A1891004
First Received:	April 17, 2007
Last Updated:	August 23, 2007
ClinicalTrials.gov Identifier:	NCT00463762
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Gallbladder Diseases

Abdominal Abscess

Cefoperazone

Gastrointestinal Diseases

Peritonitis

Wounds and Injuries

Disorders of Environmental Origin

Cholecystitis

Intestinal Diseases

Sulbactam

Digestive System Diseases

Acalculous Cholecystitis

Abscess

Appendicitis

Biliary Tract Diseases

Peritoneal Diseases

Suppuration

Gastroenteritis

Wound Infection

Additional relevant MeSH terms:

Anti-Infective Agents

Anti-Bacterial Agents

Communicable Diseases

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Enzyme Inhibitors

Infection

Pharmacologic Actions

Cecal Diseases

ClinicalTrials.gov processed this record on September 05, 2008